SubHero Banner

Gazyva® (obinutuzumab) – Expanded indication and new warning

November 16, 2017 – Genentech announced the FDA approval of Gazyva (obinutuzumab), in combination with chemotherapy followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma (FL).

Download PDF